Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Aim: Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS). Patients & metho...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों:	Liang Yen Liu, Matthew S Ji, Nhung T Nguyen, Frances E Chow, Donna M Molaie, Sean T Pianka, Richard M Green, Linda M Liau, Benjamin M Ellingson, Phioanh L Nghiemphu, Timothy F Cloughesy, Albert Lai
स्वरूप:	लेख
भाषा:	English
प्रकाशित:	Taylor & Francis Group 2019-06-01
श्रृंखला:	CNS Oncology
विषय:	bevacizumab glioblastoma glioma long term progression recurrence
ऑनलाइन पहुंच:	https://www.futuremedicine.com/doi/10.2217/cns-2019-0007

समान संसाधन

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
द्वारा: Alissa Thomas, और अन्य
प्रकाशित: (2018-01-01)

A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab
द्वारा: Josie Hayes, और अन्य
प्रकाशित: (2016-10-01)

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
द्वारा: Patrick Roth, और अन्य
प्रकाशित: (2020-06-01)

Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study
द्वारा: Bai X, और अन्य
प्रकाशित: (2024-11-01)

Bevacizumab in recurrent WHO grades II–III glioma
द्वारा: Soufyan Annakib, और अन्य
प्रकाशित: (2023-07-01)

Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab
द्वारा: Joan Manel Gasent Blesa, और अन्य
प्रकाशित: (2012-12-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
द्वारा: D. R. Naskhletashvili, और अन्य
प्रकाशित: (2015-04-01)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
द्वारा: Mesti Tanja, और अन्य
प्रकाशित: (2015-03-01)

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
द्वारा: Moire Cuncannon, और अन्य
प्रकाशित: (2019-05-01)

The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials
द्वारा: SiYao Wei, और अन्य
प्रकाशित: (2024-07-01)

Mechanism and significance of diffusion restriction followed by calcification in high-grade glioma treated with bevacizumab
द्वारा: Tomohiro Hosoya, और अन्य
प्रकाशित: (2024-11-01)

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells
द्वारा: Mesti Tanja, और अन्य
प्रकाशित: (2018-11-01)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
द्वारा: N. García-Romero, और अन्य
प्रकाशित: (2020-06-01)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
द्वारा: Masahiro Nishikawa, और अन्य
प्रकाशित: (2021-03-01)

Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis
द्वारा: Zhaoyan Chen, और अन्य
प्रकाशित: (2024-05-01)

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life
द्वारा: Kathleen Van Dyk, और अन्य
प्रकाशित: (2022-06-01)

Opportunities and Challenges for Successful Use of Bevacizumab in Pediatrics
द्वारा: Amy eBarone, और अन्य
प्रकाशित: (2013-04-01)

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
द्वारा: Hiroyuki Tatekawa, और अन्य
प्रकाशित: (2021-03-01)

Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma
द्वारा: Rebecca Kassubek, और अन्य
प्रकाशित: (2023-05-01)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
द्वारा: Celina Bihan, और अन्य
प्रकाशित: (2012-09-01)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
द्वारा: Eudocia Q. Lee, और अन्य
प्रकाशित: (2019-10-01)

Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center
द्वारा: Margarida Simão-Rafael, और अन्य
प्रकाशित: (2023-12-01)

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping
द्वारा: Pia Banerjee, और अन्य
प्रकाशित: (2015-01-01)

Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine
द्वारा: Ramon F. Barajas, और अन्य
प्रकाशित: (2016-10-01)

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
द्वारा: George Ansstas, और अन्य
प्रकाशित: (2016-01-01)

Differential expression of the circadian clock network correlates with tumour progression in gliomas
द्वारा: Marina Petkovic, और अन्य
प्रकाशित: (2023-07-01)

Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
द्वारा: Barbara Castelli, और अन्य
प्रकाशित: (2023-09-01)

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
द्वारा: Giovanni Luca Gravina, और अन्य
प्रकाशित: (2017-01-01)

Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis
द्वारा: Dong Liu, और अन्य
प्रकाशित: (2024-07-01)

Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
द्वारा: Barbara Castelli, और अन्य
प्रकाशित: (2024-02-01)

Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab
द्वारा: Samy Ammari, और अन्य
प्रकाशित: (2021-07-01)

Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review
द्वारा: Oguz Ozel, और अन्य
प्रकाशित: (2016-08-01)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
द्वारा: Emil Lou, और अन्य
प्रकाशित: (2013-04-01)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
द्वारा: Seung Won Choi, और अन्य
प्रकाशित: (2018-05-01)

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
द्वारा: Minjie Fu, और अन्य
प्रकाशित: (2023-06-01)

Circadian Alterations in a Murine Model of Hypothalamic Glioma
द्वारा: José M. Duhart, और अन्य
प्रकाशित: (2017-10-01)

Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines
द्वारा: Valerie J. Marallano, और अन्य
प्रकाशित: (2024-03-01)

Selected cytostatic drugs in the treatment of brain glioma – literature review
द्वारा: Jarosław Bała, और अन्य
प्रकाशित: (2021-11-01)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
द्वारा: Lei She, और अन्य
प्रकाशित: (2022-08-01)

A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy
द्वारा: Shanmu Jin, और अन्य
प्रकाशित: (2024-03-01)